Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 2
2014 2
2015 1
2016 4
2017 4
2018 2
2019 3
2020 3
2021 2
2022 1
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
van Amerongen RA, Tuit S, Wouters AK, van de Meent M, Siekman SL, Meeuwsen MH, Wachsmann TLA, Remst DFG, Hagedoorn RS, van der Steen DM, de Ru AH, Verdegaal EME, van Veelen PA, Falkenburg JHF, Heemskerk MHM. van Amerongen RA, et al. Among authors: verdegaal eme. Front Immunol. 2023 Mar 21;14:1121973. doi: 10.3389/fimmu.2023.1121973. eCollection 2023. Front Immunol. 2023. PMID: 37026005 Free PMC article.
Neoantigen Targetability in Progressive Advanced Melanoma.
van den Bulk J, Verdegaal EME, van der Ploeg M, Visser M, Nunes JB, de Ru AH, Tjokrodirijo RTN, Ijsselsteijn ME, Janssen NI, van der Breggen R, de Bruin L, de Kok P, Janssen GMC, Ruano D, Kapiteijn EHW, van Veelen PA, de Miranda NFCC, van der Burg SH. van den Bulk J, et al. Among authors: verdegaal eme. Clin Cancer Res. 2023 Oct 13;29(20):4278-4288. doi: 10.1158/1078-0432.CCR-23-1106. Clin Cancer Res. 2023. PMID: 37540567 Free PMC article.
CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden.
van den Bulk J, van der Ploeg M, Ijsselsteijn ME, Ruano D, van der Breggen R, Duhen R, Peeters KCMJ, Fariña-Sarasqueta A, Verdegaal EME, van der Burg SH, Duhen T, de Miranda NFCC. van den Bulk J, et al. Among authors: verdegaal eme. J Immunother Cancer. 2023 Feb;11(2):e005887. doi: 10.1136/jitc-2022-005887. J Immunother Cancer. 2023. PMID: 36792124 Free PMC article.
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.
de Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JB, Toes REM, van der Woude D. de Moel EC, et al. Among authors: verdegaal eme. Cancer Immunol Res. 2019 Jan;7(1):6-11. doi: 10.1158/2326-6066.CIR-18-0245. Epub 2018 Nov 13. Cancer Immunol Res. 2019. PMID: 30425107
Identification of non-mutated neoantigens presented by TAP-deficient tumors.
Marijt KA, Blijleven L, Verdegaal EME, Kester MG, Kowalewski DJ, Rammensee HG, Stevanović S, Heemskerk MHM, van der Burg SH, van Hall T. Marijt KA, et al. Among authors: verdegaal eme. J Exp Med. 2018 Sep 3;215(9):2325-2337. doi: 10.1084/jem.20180577. Epub 2018 Aug 16. J Exp Med. 2018. PMID: 30115740 Free PMC article.
Neoantigen landscape dynamics during human melanoma-T cell interactions.
Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H, Haanen JB, Kapiteijn EH, Schumacher TN, van der Burg SH. Verdegaal EM, et al. Nature. 2016 Aug 4;536(7614):91-5. doi: 10.1038/nature18945. Epub 2016 Jun 27. Nature. 2016. PMID: 27350335
28 results